Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. The pipeline of Aggrescan3D 2.0 server.

Published by舟锯 谭 Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. The pipeline of Aggrescan3D 2.0 server."— Presentation transcript:

1 Figure 1. The pipeline of Aggrescan3D 2.0 server.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Nucleic Acids Res, gkz321, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Aggregation propensity for different multimeric proteins, calculated in static or dynamic modes. (A) The ... Figure 2. Aggregation propensity for different multimeric proteins, calculated in static or dynamic modes. (A) The aggregation propensity of the static input structure relative to that of the 12 dynamic models is represented for homodimers, heterodimers, antibodies or the complete set. In the color scale, dark blue indicates the static structure being the most soluble (ranking 1) and dark red the static structure being the most aggregation-prone (ranking 13). (B) Monoclonal antibody bevacizumab Fab fragment (PDB: 1BJ1) ran on static (left) or dynamic (right) modes. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Nucleic Acids Res, gkz321, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. A3D 2.0 as a tool for the in silico redesign of more stable and soluble proteins. A3D structures of original ... Figure 3. A3D 2.0 as a tool for the in silico redesign of more stable and soluble proteins. A3D structures of original GFP (left) (PDB: 2B3Q:A) and engineered GFP/KKK mutant (right) (PDB: 6FWW) coloured according to the A3D score. Mutations lowering aggregation propensity, while maintaining protein stability are encircled. The mutated variant was experimentally shown to be 2-fold more resistant against aggregation (19). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Nucleic Acids Res, gkz321, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Automated mutations for variable heavy (VH) segment of a human germline antibody. (A) A3D 2.0 automated ... Figure 4. Automated mutations for variable heavy (VH) segment of a human germline antibody. (A) A3D 2.0 automated mutations output (the residues at the three antibody CDRs were excluded from the screening). (B) The blue highlighted mutations in panel A were combined to render triple mutant engineered antibody. Structures of wild type (PDB: 5I19) and the mutant, as predicted by A3D 2.0. Solubilizing mutations are encircled. The engineered antibody variant was experimentally shown to be 3-fold more resistant against aggregation (19). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Nucleic Acids Res, gkz321, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. The pipeline of Aggrescan3D 2.0 server."

Similar presentations

From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
Fig. 1. RUbioSeq pipelines for exome variant detection and BS-Seq analyses. Dark gray boxes correspond to the main steps of the pipelines. Light gray boxes.

Fig. 1. RUbioSeq pipelines for exome variant detection and BS-Seq analyses. Dark gray boxes correspond to the main steps of the pipelines. Light gray boxes.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
From: Dynamic protein–RNA interactions in mediating splicing catalysis

From: Dynamic protein–RNA interactions in mediating splicing catalysis
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.

Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.

Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.
Figure 1. autoMLST workflow depicting placement and de novo mode

Figure 1. autoMLST workflow depicting placement and de novo mode

Similar presentations

Ads by Google